Information for staff regarding construction and redevelopment

Infection risks associated with construction and redevelopment

Many types of fungi and bacteria can be disturbed during demolition and construction in healthcare facilities. This increases the risk that immune compromised patients will develop invasive infections such as Aspergillosis.

Organisms that can be implicated in human disease during demolition and construction (list not exhaustive)

Aspergillus species (A. fumigatus,
A. flavus, A. niger, A. terreus,
and A. nidulans)

Bacillus species

Legionellae
Scedosporium
Histoplasma capsulatum

Coccidioides immitis
Pneumocystis carinii
Mucorales 
(e.g., Rhizopus)
Fusarium species

Patient risk

Most people are exposed to fungus such as Aspergillus at some time during their lives, but never develop an infection. Aspergillus spores are often present in the air and carried on wind currents from environmental sources. Healthy people usually inhale these spores without becoming sick. However, for patients who are immunocompromised, increased concentrations of Aspergillus spores in the air because of construction works may lead to severe invasive fungal infection. Such infections pose an increased risk of mortality for these patients.

Patients at highest risk are:

  • neonates and infants,
  • receiving immunosuppressive or cytotoxic therapy,
  • transplant recipients,
  • HIV infection, and
  • those with granulomatous disease.

The incubation period can be a few days to months. Common clinical presentations include pneumonia, sinusitis, or invasive aspergillosis or other invasive fungal infection. Aspergillus is not spread person to person.

Preventing infection risks with construction and redevelopment

While all steps will be taken to reduce environmental risks posed by construction activities, dust may still be generated during this work. Please report any concerns you identify with dust to your line manager and the Infection Prevention and Control team.

Staff should never enter construction zones unless authorised.

Refer to Table 1 for information regarding individual risk factors to consider. All patients in categories 2-4 should wear a surgical mask when travelling in or out of the facility through any external zone impacted by construction.

Additionally, patients at increased risk of invasive fungal infections as per Table 1 (Category 2-4), where practicable, may need to be moved to an area well away from the works. Patients at the highest risk (Category 4), may need to be placed into a HEPA filtered positive pressure room or unit.

A high index of suspicion for the diagnosis of fungal infections such as Aspergillosis should be maintained for those persons identified as being at risk (Category 2-4) and ongoing surveillance through clinical and microbiological/histological specimen.

Individual risk factors to consider for invasive fungal infection

Category 1

  • Staff members, service providers and contractors.
  • All patients not listed in Groups 2 - 4 below.

Category 2

  • Patients on prolonged courses of high dose steroids particularly those hospitalised for prolonged periods.
  • Severely immuno-suppressed patients living with HIV.
  • Patients undergoing mechanical ventilation.
  • Patients having chemotherapy who are not neutropenic.*
  • Dialysis patients.

*Neutropenia defined as absolute neutrophil count (ANC), <1x109/l

Category 3

  • Neutropenia* for less than 14 days following chemotherapy.
  • Solid organ transplantation.
  • Neonates in intensive care units (ICU).

*Neutropenia defined as absolute neutrophil count (ANC), <1x109/l

Category 4

  • Allogenic bone marrow transplantation: within 12 months of transplant; if >12 months, consult with haematologist.
  • Autologous peripheral blood stem cell transplantation, i.e., during the neutropenic period.
  • Prolonged neutropenia for greater than 14 days following chemotherapy or immunosuppressive therapy: e.g., acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Burkitt’s lymphoma, lymphoblastic lymphoma, primary CNS lymphoma.
  • Aplastic anaemia patients.
  • Children with:
    • Severe Combined Immunodeficiency Syndrome (SCIDS).
    • Chronic Granulomatous Disease of Childhood (CGDC).

*Neutropenia defined as absolute neutrophil count (ANC), <1x109/l

Last updated: 29 January 2025